Literature DB >> 16087767

Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam Study.

Lonneke M L de Lau1, C Maarten A Schipper, Albert Hofman, Peter J Koudstaal, Monique M B Breteler.   

Abstract

BACKGROUND: Most prognostic studies on Parkinson disease have been hospital based or have applied register-based case-finding methods. Potential under-representation of mild cases may have given biased results.
OBJECTIVE: To evaluate whether Parkinson disease is associated with an increased risk of dementia and death.
DESIGN: Population-based cohort study. Parkinson disease and dementia were assessed through in-person examination at baseline (1990-1993) and 2 follow-up visits (1993-1994 and 1997-1999). Computerized linkage to medical and municipality records provided additional information on disease outcomes and mortality.
SETTING: General population. PARTICIPANTS: A total of 6969 participants, including 99 prevalent and 67 incident cases of Parkinson disease. MAIN OUTCOME MEASURES: Incident dementia and death. Adjusted hazard ratios were calculated through Cox proportional hazards regression analysis.
RESULTS: Patients with Parkinson disease had an increased risk of dementia (hazard ratio, 2.8; 95% confidence interval, 1.8-4.4), which was especially pronounced in participants carrying at least 1 apolipoprotein E gene (APOE) epsilon2 allele (13.5; 4.5-40.6). Parkinson disease was associated with an increased mortality risk (1.8; 1.5-2.3). The association consistently diminished when analyses were sequentially restricted to patients with shorter disease duration and after adjustment for the occurrence of dementia.
CONCLUSIONS: Especially patients with Parkinson disease who carry an APOE epsilon2 allele have an increased risk of developing dementia. Increased mortality risk in Parkinson disease is dependent on disease duration and is only modest in the absence of dementia.

Entities:  

Mesh:

Year:  2005        PMID: 16087767     DOI: 10.1001/archneur.62.8.1265

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  55 in total

Review 1.  Biomarkers for cognitive impairment in Parkinson disease.

Authors:  Min Shi; Bertrand R Huber; Jing Zhang
Journal:  Brain Pathol       Date:  2010-05       Impact factor: 6.508

2.  Long-term cognitive outcome of bilateral subthalamic deep brain stimulation in Parkinson's disease.

Authors:  Han-Joon Kim; Beom S Jeon; Sun Ha Paek; Kyoung-Min Lee; Ji-Young Kim; Jee-Young Lee; Hee Jin Kim; Ji Young Yun; Young Eun Kim; Hui-Jun Yang; Gwanhee Ehm
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

3.  Neurocognitive and atrophic patterns in Parkinson's disease based on subjective memory complaints.

Authors:  Jin Yong Hong; Ji Eun Lee; Young H Sohn; Phil Hyu Lee
Journal:  J Neurol       Date:  2012-08       Impact factor: 4.849

4.  Estimated life expectancy of Parkinson's patients compared with the UK population.

Authors:  Lianna S Ishihara; Anne Cheesbrough; Carol Brayne; Anette Schrag
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-30       Impact factor: 10.154

Review 5.  Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers.

Authors:  Alexander I Tröster
Journal:  Neuropsychol Rev       Date:  2008-03-06       Impact factor: 7.444

6.  Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.

Authors:  Job F M van Boven; Annoesjka Novak; Maurice T Driessen; Cornelis Boersma; Maarten M Boomsma; Maarten J Postma
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

7.  The Movement Disorders Society criteria for the diagnosis of Parkinson's disease dementia: their usefulness and limitations in elderly patients.

Authors:  Michèle Kiesmann; Jean-Baptiste Chanson; Julien Godet; Thomas Vogel; Laetitia Schweiger; Saïd Chayer; Georges Kaltenbach
Journal:  J Neurol       Date:  2013-07-09       Impact factor: 4.849

8.  Use of an entacapone-containing drug combination and risk of death: Analysis of the FDA AERS (FAERS) database.

Authors:  Thamir M Alshammari; Eman N AlMutairi
Journal:  Saudi Pharm J       Date:  2014-04-30       Impact factor: 4.330

Review 9.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

10.  Estimating dementia-free life expectancy for Parkinson's patients using Bayesian inference and microsimulation.

Authors:  Ardo van den Hout; Fiona E Matthews
Journal:  Biostatistics       Date:  2009-07-31       Impact factor: 5.899

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.